Platelet-rich plasma-derived exosomes boost mesenchymal stem cells to promote peripheral nerve regeneration

J Control Release. 2024 Mar:367:265-282. doi: 10.1016/j.jconrel.2024.01.043. Epub 2024 Jan 29.

Abstract

Peripheral nerve injury (PNI) remains a severe clinical problem with debilitating consequences. Mesenchymal stem cell (MSC)-based therapy is promising, but the problems of poor engraftment and insufficient neurotrophic effects need to be overcome. Herein, we isolated platelet-rich plasma-derived exosomes (PRP-Exos), which contain abundant bioactive molecules, and investigated their potential to increase the regenerative capacity of MSCs. We observed that PRP-Exos significantly increased MSC proliferation, viability, and mobility, decreased MSC apoptosis under stress, maintained MSC stemness, and attenuated MSC senescence. In vivo, PRP-Exo-treated MSCs (pExo-MSCs) exhibited an increased retention rate and heightened therapeutic efficacy, as indicated by increased axonal regeneration, remyelination, and recovery of neurological function in a PNI model. In vitro, pExo-MSCs coculture promoted Schwann cell proliferation and dorsal root ganglion axon growth. Moreover, the increased neurotrophic behaviour of pExo-MSCs was mediated by trophic factors, particularly glia-derived neurotrophic factor (GDNF), and PRP-Exos activated the PI3K/Akt signalling pathway in MSCs, leading to the observed phenotypes. These findings demonstrate that PRP-Exos may be novel agents for increasing the ability of MSCs to promote neural repair and regeneration in patients with PNI.

Keywords: Cell therapy; Glia-derived neurotrophic factor; Nerve regeneration; Peripheral nerve injury; Platelet-rich plasma-derived exosomes; Umbilical cord-derived mesenchymal stem cell.

MeSH terms

  • Exosomes* / metabolism
  • Humans
  • Mesenchymal Stem Cells*
  • Nerve Regeneration
  • Peripheral Nerve Injuries* / therapy
  • Phosphatidylinositol 3-Kinases / metabolism
  • Platelet-Rich Plasma*

Substances

  • Phosphatidylinositol 3-Kinases